HER2表达与乳腺癌预后的相关性研究

为了研究乳腺癌HER2表达与预后的关系 ,探讨其作为乳腺癌预后指标的可行性 ,采用免疫组化法 (IHC)检测 185例乳腺癌标本的HER2表达 ,并随访其生存时间。 185例中失访 6 5例 ;12 0例有 10年预后随访资料 ,其中死亡 2 8例。所有检测标本的HER2的阳性率为 37 3%;不同HER2表达级别生存曲线比较差异有统计学意义 ,各生存曲线之间比较差异有统计学意义 ,P值均小于 0 0 1;HER2阴性者 40和 6 0个月生存率比高表达患者高 ;HER2过度表达与生存期呈负相关(P <0 0 5 )。结果说明 ,乳腺癌患者HER2高表达预示生存时间缩短 ,HER2是乳腺癌预后不良的一项独立指标。

RESEARCH ON THE RELATIONSHIP BETWEEN THE PROGNOSIS AND THE EXPRESSION OF HER2 IN BREAST CANCER

To investigate the relationship between the prognosis and the HER-2 expression and its significance as a prognosis predictor in patients with breast cancer. In 185 samples of breast cancer the expression of HER-2 was immunchistochemically deternined and the survival time of the patients was respectivaly affirmed. 120 patients (64.9%) with complete followed-up data were indudal, of whom 28 patients died (15%). The records of other 65 patients (35.1%) were not available for this study. It was showed that the positive rate for HER2 was 37.3%. There was significant difference between the survival curves in patients exhibiting different grades of HER2 expression (P<0.01). The survival rate of patients with negative HER2 expression was higher than that of HER2 positive (grade 3) ones in the fortieth month and the sixtieth month. The overexpression of HER2 was in negative correlation with survival time (P<0.05). It is concluded that HER2 is an independent predictor of prognosis, and high expression of HER2 was predictive of a short survival time.